Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Acquired by BNP Paribas Financial Markets

BNP Paribas Financial Markets raised its position in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 88.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 305,480 shares of the biopharmaceutical company's stock after buying an additional 143,781 shares during the quarter. BNP Paribas Financial Markets owned about 0.62% of Theravance Biopharma worth $2,462,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. Squarepoint Ops LLC bought a new position in Theravance Biopharma in the 2nd quarter valued at $986,000. Bank of Montreal Can raised its stake in shares of Theravance Biopharma by 141.0% during the second quarter. Bank of Montreal Can now owns 160,138 shares of the biopharmaceutical company's stock worth $1,414,000 after acquiring an additional 93,702 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Theravance Biopharma by 38.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 330,181 shares of the biopharmaceutical company's stock worth $2,800,000 after acquiring an additional 91,679 shares during the last quarter. Algert Global LLC bought a new stake in Theravance Biopharma in the third quarter worth $851,000. Finally, Marshall Wace LLP grew its stake in shares of Theravance Biopharma by 83.6% during the second quarter. Marshall Wace LLP now owns 297,499 shares of the biopharmaceutical company's stock valued at $2,523,000 after buying an additional 135,426 shares during the last quarter. Hedge funds and other institutional investors own 99.10% of the company's stock.

Insider Activity at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the company's stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the sale, the senior vice president now owns 322,743 shares in the company, valued at approximately $2,904,687. This represents a 1.22 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 6.90% of the stock is currently owned by corporate insiders.

Theravance Biopharma Trading Up 0.4 %

Shares of TBPH stock traded up $0.04 on Friday, reaching $9.88. The company's stock had a trading volume of 132,468 shares, compared to its average volume of 230,087. Theravance Biopharma, Inc. has a 1 year low of $7.44 and a 1 year high of $11.71. The company has a market capitalization of $485.80 million, a price-to-earnings ratio of -9.78 and a beta of 0.23. The stock's fifty day simple moving average is $8.86 and its 200-day simple moving average is $8.72.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.16). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. The company had revenue of $16.87 million for the quarter, compared to analysts' expectations of $16.11 million. During the same period in the prior year, the firm posted ($0.17) earnings per share. Equities research analysts forecast that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. HC Wainwright reissued a "buy" rating and set a $15.00 price objective on shares of Theravance Biopharma in a research note on Monday, September 16th. StockNews.com cut Theravance Biopharma from a "buy" rating to a "hold" rating in a report on Saturday, August 10th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, Theravance Biopharma currently has an average rating of "Hold" and an average price target of $13.75.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.